VEGF and IGF Delivered from Alginate Hydrogels Promote Stable Perfusion Recovery in Ischemic Hind Limbs of Aged Mice and Young Rabbits

Biomaterial-based delivery of angiogenic growth factors restores perfusion more effectively than bolus delivery methods in rodent models of peripheral vascular disease, but the same success has not yet been demonstrated in clinically relevant studies of aged or large animals. These studies explore, in clinically relevant models, a therapeutic angiogenesis strategy for the treatment of peripheral vascular disease that overcomes the challenges encountered in previous clinical trials. Alginate hydrogels providing sustained release of vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF) were injected into ischemic hind limbs in middle-aged and old mice, and also in young rabbits, as a test of the scalability of this local growth factor treatment. Spontaneous perfusion recovery diminished with increasing age, and only the combination of VEGF and IGF delivery from gels significantly rescued perfusion in middle-aged (13 months) and old (20 months) mice. In rabbits, the delivery of VEGF alone or in combination with IGF from alginate hydrogels, at a dose 2 orders of magnitude lower than the typical doses used in past rabbit studies, enhanced perfusion recovery when given immediately after surgery, or as a treatment for chronic ischemia. Capillary density measurements and angiographic analysis demonstrated the benefit of gel delivery. These data together suggest that alginate hydrogels providing local delivery of low doses of VEGF and IGF constitute a safe and effective treatment for hind-limb ischemia in clinically relevant animal models, thereby supporting the potential clinical translation of this concept.

[1]  O. Mendiz,et al.  High‐dose plasmid‐mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (Genesis‐I). A phase I, open‐label, two‐year follow‐up trial , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[2]  R. Lederman,et al.  Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial , 2002, The Lancet.

[3]  D. Mooney,et al.  Polymeric system for dual growth factor delivery , 2001, Nature Biotechnology.

[4]  I. Torres-Aleman,et al.  Insulin-like growth factor I is required for vessel remodeling in the adult brain. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[5]  S. Dunn.  Insulin-like growth factor I stimulate angiogenesis and the production of vascular endothelial growth factor , 2000 .

[6]  David J Mooney,et al.  Effects of VEGF temporal and spatial presentation on angiogenesis. , 2010, Biomaterials.

[7]  Brian H Annex,et al.  A target‐mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans , 2002, Clinical pharmacology and therapeutics.

[8]  R K Jain,et al.  Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. , 1996, The American journal of pathology.

[9]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[10]  D. Hume,et al.  CSF‐1, IGF‐1, and the control of postnatal growth and development , 2010, Journal of leukocyte biology.

[11]  J. Olin,et al.  Peripheral artery disease. Part 1: clinical evaluation and noninvasive diagnosis , 2011, Nature Reviews Cardiology.

[12]  J. Isner,et al.  Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. , 1999, The Journal of clinical investigation.

[13]  R. Hendel,et al.  Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. , 2001, American heart journal.

[14]  G. Moneta.  Effect of Hypoxia-Inducible Factor-1α Gene Therapy on Walking Performance in Patients With Intermittent Claudication , 2012 .

[15]  R. Morishita,et al.  Gene Therapy and Cell-Based Therapies for Therapeutic Angiogenesis in Peripheral Artery Disease , 2013, BioMed research international.

[16]  A. Klip,et al.  Cross-talk between skeletal muscle and immune cells: muscle-derived mediators and metabolic implications. , 2013, American journal of physiology. Endocrinology and metabolism.

[17]  C. Stewart,et al.  Potentiation of insulin-like growth factor-I (IGF-I) activity by an antibody: supportive evidence for enhancement of IGF-I bioavailability in vivo by IGF binding proteins. , 1993, Endocrinology.

[18]  Eben Alsberg,et al.  Degradation of Partially Oxidized Alginate and Its Potential Application for Tissue Engineering , 2001, Biotechnology progress.

[19]  I. Zachary,et al.  Therapeutic angiogenesis for cardiovascular disease: biological context, challenges, prospects , 2010, Heart.

[20]  R. Morishita,et al.  Results of a Double-Blind, Placebo-Controlled Study to Assess the Safety of Intramuscular Injection of Hepatocyte Growth Factor Plasmid to Improve Limb Perfusion in Patients With Critical Limb Ischemia , 2008, Circulation.

[21]  Jeff W Lichtman,et al.  Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors , 2009, Proceedings of the National Academy of Sciences.

[22]  Brian H Annex,et al.  Claudication of Vascular Endothelial Growth Factor 121 in Patients With Disabling Intermittent Disease : A Phase II Randomized , Double-Blind , Controlled Study of Adenoviral Delivery Regional Angiogenesis With Vascular Endothelial Growth Factor in Peripheral Arterial , 2003 .

[23]  S. Epstein,et al.  Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. , 1996, Circulation.

[24]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[25]  L. Norgren,et al.  Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). , 2007, Journal of vascular surgery.

[26]  Crystal M. Botham,et al.  Clinical trials of adult stem cell therapy for peripheral artery disease. , 2013, Methodist DeBakey cardiovascular journal.

[27]  P. Hutchins,et al.  Decreases in cerebral microvasculature with age are associated with the decline in growth hormone and insulin-like growth factor 1. , 1997, Endocrinology.

[28]  David J Mooney,et al.  Integrated approach to designing growth factor delivery systems , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  B. Lévy,et al.  Post-ischaemic neovascularization and inflammation. , 2008, Cardiovascular research.

[30]  David J Mooney,et al.  Alginate hydrogels as biomaterials. , 2006, Macromolecular bioscience.

[31]  Brian H Annex,et al.  The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis , 2003 .

[32]  L. Norgren,et al.  Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia , 2011, The Lancet.

[33]  David J Mooney,et al.  Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. , 2005, Biomaterials.

[34]  F. Vermassen,et al.  Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  J. Isner,et al.  Age-dependent impairment of angiogenesis. , 1999, Circulation.

[36]  S. Welle.  Gene transcript profiling in aging research , 2002, Experimental Gerontology.

[37]  P. Fagenholz,et al.  Hypoxia and inflammation. , 2011, The New England journal of medicine.

[38]  J. Gerss,et al.  Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery disease , 2011, Gene Therapy.

[39]  W. Shannon,et al.  Meeting the need for regenerative therapies: translation-focused analysis of U.S. regenerative medicine opportunities in cardiovascular and peripheral vascular medicine using detailed incidence data. , 2013, Tissue engineering. Part B, Reviews.

[40]  D. Mooney,et al.  Promoting angiogenesis via manipulation of VEGF responsiveness with notch signaling. , 2009, Biomaterials.

[41]  S. Dunn.  Insulin-like growth factor I stimulates angiogenesis and the production of vascular endothelial growth factor. , 2000, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[42]  B. Lévy,et al.  Postischemic revascularization: from cellular and molecular mechanisms to clinical applications. , 2013, Physiological reviews.

[43]  N. Geifman,et al.  The Mouse Age Phenome Knowledgebase and Disease-Specific Inter-Species Age Mapping , 2013, PloS one.

[44]  D J Mooney,et al.  Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis , 2007, Journal of thrombosis and haemostasis : JTH.